Home > Publications database > P14.32 Spatial discrepancies between FET PET and conventional MRI in patients with newly diagnosed glioblastoma > print

001     908209
005     20220923174122.0
024 7 _ |a 10.1093/neuonc/noz126.267
|2 doi
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a WOS:000493085900269
|2 WOS
037 _ _ |a FZJ-2022-02460
082 _ _ |a 610
100 1 _ |a Lohmann, P.
|0 P:(DE-Juel1)145110
|b 0
|u fzj
245 _ _ |a P14.32 Spatial discrepancies between FET PET and conventional MRI in patients with newly diagnosed glioblastoma
260 _ _ |c 2019
336 7 _ |a Text
|2 DataCite
336 7 _ |a Communication
|b comm
|m comm
|0 PUB:(DE-HGF)4
|s 1655805449_15481
|2 PUB:(DE-HGF)
336 7 _ |a MISC
|2 BibTeX
336 7 _ |a OTHER
|2 ORCID
336 7 _ |a Other
|2 DINI
336 7 _ |a Personal Communication
|0 4
|2 EndNote
520 _ _ |a AbstractBACKGROUNDIn patients with glioblastoma, the tissue showing contrast enhancement (CE) in MRI is usually the target for resection or radiotherapy. However, the solid tumor mass typically extends beyond the area of CE. Amino acid PET can detect tumor parts that show no CE. We systematically investigated tumor volumes delineated by amino acid PET and MRI in newly diagnosed, untreated glioblastoma patients.MATERIAL AND METHODSPreoperatively, 50 patients with subsequently neuropathologically confirmed glioblastoma underwent O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET, fluid-attenuated inversion recovery (FLAIR), and CE MRI. Areas of CE were manually delineated. FET PET tumor volumes were segmented using a tumor-to-brain ratio ≥ 1.6. The percentage of overlapping volumes (OV), as well as Dice and Jaccard spatial similarity coefficients (DSC; JSC), were calculated. FLAIR images were evaluated visually.RESULTSIn 86% of patients (n = 43), the FET PET tumor volume was significantly larger than the volume of CE (21.5 ± 14.3 mL vs. 9.4 ± 11.3 mL; P < 0.001). Forty patients (80%) showed both an increased uptake of FET and CE. In these 40 patients, the spatial similarity between FET and CE was low (mean DSC, 0.39 ± 0.21; mean JSC, 0.26 ± 0.16). Ten patients (20%) showed no CE, and one of these patients showed no FET uptake. In 10% of patients (n = 5), increased FET uptake was present outside of areas of FLAIR hyperintensity.CONCLUSIONOur results show that the metabolically active tumor volume delineated by FET PET is significantly larger than tumor volume delineated by CE. The data strongly suggest that the information derived from FET PET should be integrated into the management of newly diagnosed glioblastoma patients.FUNDINGThis work was supported by the Wilhelm-Sander Stiftung, Germany
536 _ _ |a 5253 - Neuroimaging (POF4-525)
|0 G:(DE-HGF)POF4-5253
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Stavrinou, P.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Lipke, K.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Bauer, E. K.
|0 P:(DE-Juel1)159312
|b 3
|u fzj
700 1 _ |a Ceccon, G.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Werner, J.
|b 5
700 1 _ |a Fink, G. R.
|0 P:(DE-Juel1)131720
|b 6
|u fzj
700 1 _ |a Shah, N. J.
|0 P:(DE-Juel1)131794
|b 7
|u fzj
700 1 _ |a Langen, K.
|0 P:(DE-Juel1)131777
|b 8
|u fzj
700 1 _ |a Galldiks, N.
|0 P:(DE-Juel1)143792
|b 9
|u fzj
773 _ _ |a 10.1093/neuonc/noz126.267
|0 PERI:(DE-600)2094060-9
|y 2019
|g Vol. 21, no. Supplement_3, p. iii74 - iii74
|x 1523-5866
909 C O |o oai:juser.fz-juelich.de:908209
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)145110
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)159312
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131720
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)131794
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)131777
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 9
|6 P:(DE-Juel1)143792
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5253
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-02-03
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-03
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2019
|d 2021-02-03
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NEURO-ONCOLOGY : 2019
|d 2021-02-03
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 0
920 1 _ |0 I:(DE-Juel1)INM-11-20170113
|k INM-11
|l Jara-Institut Quantum Information
|x 1
920 1 _ |0 I:(DE-Juel1)VDB1046
|k JARA-BRAIN
|l Jülich-Aachen Research Alliance - Translational Brain Medicine
|x 2
980 _ _ |a comm
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a I:(DE-Juel1)INM-11-20170113
980 _ _ |a I:(DE-Juel1)VDB1046
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21